Journal Article (Review Article) DKFZ-2019-00924

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Circulating MicroRNA Biomarkers for Lung Cancer Detection in East Asian Populations.

 ;  ;  ;  ;

2019
MDPI Basel

Cancers 11(3), 415 () [10.3390/cancers11030415]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Lung cancer (LC) is the leading cause of cancer-related death in Eastern Asia. The prognosis of LC highly depends on tumor stages and early detection could substantially reduce LC mortality. Accumulating evidence suggested that circulating miRNAs in plasma or serum may have applications in early LC detection. We thus conducted a systematic literature review on the diagnostic value of miRNAs markers for LC in East Asian populations.PubMed and ISI Web of Knowledge were searched to retrieve relevant articles published up to 17 September 2018. Information on study design, population characteristics, investigated miRNAs and diagnostic accuracy (including sensitivity, specificity and area under the curve (AUC)) were independently extracted by two reviewers.Overall, 46 studies that evaluated a total of 88 miRNA markers for LC diagnosis in East Asian populations were identified. Sixteen of the 46 studies have incorporated individual miRNA markers as panels (with 2⁻20 markers). Three promising miRNA panels with ≥90% sensitivity and ≥90% specificity were discovered, two of which were externally validated. Diagnostic performance of circulating miRNAs in East Asian populations was comparable to previously summarized performance in Western populations. Forty-four miRNAs were reported in both populations. No major differences in diagnostic performance by ethnicity of the same miRNA was observed.Circulating miRNAs or miRNA panels, possibly in combination with other promising molecular markers including epigenetic and genetic markers, may be promising candidates for noninvasive LC early detection. However, large studies with samples collected prospectively in true screening settings are required to validate the promising markers or marker panels.

Classification:

Contributing Institute(s):
  1. Klinische Epidemiologie und Alternsforschung (C070)
  2. Präventive Onkologie (C120)
  3. DKTK Heidelberg (L101)
Research Program(s):
  1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2019
Database coverage:
Medline ; Creative Commons Attribution CC BY (No Version) ; DOAJ ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2019-04-05, last modified 2024-02-29



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)